RxDoctor Payments Data

Kimberly Rohan

Oncology · Naperville, ILNPI 1982749750

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $142,059 of the $192,181 with a category attached, or 73.9%. 36 manufacturers reported payments, led by AstraZeneca at 40.2% of the total.

$192,181in general payments, 2019–2025

Across 386 payments — averaging $497.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$77K
  • Regeneron Healthcare Solutions, Inc.$73K
  • Sanofi$17K
  • Takeda Pharmaceuticals U.S.A., Inc.$6K
  • G1 Therapeutics, Inc.$5K
  • Pharmacosmos Therapeutics Inc.$4K
  • plus $10K from 30 others

What the payments were for

  • Consulting fees$10,8916%
  • Speaking & faculty fees$142,05974%
  • Travel & lodging$29,08415%
  • Food & beverage$8,8995%
  • Education$1,2481%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few oncology providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Other oncology in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →